<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461966</url>
  </required_header>
  <id_info>
    <org_study_id>Aflatoxin</org_study_id>
    <nct_id>NCT02461966</nct_id>
  </id_info>
  <brief_title>Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta</brief_title>
  <official_title>Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend
      of risk factors differs in different parts of the world, and this may explain in part the
      diverse biologic characteristics of HCC in different populations .

      Exposure to aflatoxin is an additional risk factor for the development of HCC, through damage
      of DNA in liver cells and mutation in p53 tumor suppressor gene . A previous study showed
      that aflatoxin B1 has a considerable role in the development of HCC among Egyptians .

      Clinical studies have shown that AFB1 selectively targets at the third base position of codon
      249 of the human p53 gene, a known mutational hotspot in human hepatocellular carcinoma (HCC)
      . A significant association between aflatoxin exposure and HCC has been reported in
      hyperendemic areas . A synergistic interaction between AFB1 exposure and viral hepatitis B
      (HBV) infection on HCC risk has been reported in several epidemiologic studies.

      Aflatoxin exposure may be associated with advanced liver disease in chronic hepatitis C (HCV)
      patients. Levels of AFB1-albumin/albumin were significantly related to ultrasono-graphic
      hepatic parenchyma scores in anti-HCV-positive subjects .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the third
      most common cause of cancer-related deaths complicating liver cirrhosis in most cases.

      In Egypt, there has been a remarkable increase of the proportion of HCC among chronic liver
      diseases (CLD) patients from 4.0% to 7.2% over a decade. This rising proportion may be
      explained by the increasing risk factors such as the emergence of hepatitis C virus (HCV)
      over the same period of time, the contribution of hepatitis B virus (HBV) infection,
      improvement of the screening programs and diagnostic tools of HCC as well as the increased
      survival rate among patients with cirrhosis to allow time for some of them to develop HCC .

      Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend
      of risk factors differs in different parts of the world, and this may explain in part the
      diverse biologic characteristics of HCC in different populations .

      Exposure to aflatoxin is an additional risk factor for the development of HCC, through damage
      of DNA in liver cells and mutation in p53 tumor suppressor gene . A previous study showed
      that aflatoxin B1 has a considerable role in the development of HCC among Egyptians .

      Clinical studies have shown that AFB1 selectively targets at the third base position of codon
      249 of the human p53 gene, a known mutational hotspot in human hepatocellular carcinoma (HCC)
      . A significant association between aflatoxin exposure and HCC has been reported in
      hyperendemic areas . A synergistic interaction between AFB1 exposure and viral hepatitis B
      (HBV) infection on HCC risk has been reported in several epidemiologic studies.

      Aflatoxin exposure may be associated with advanced liver disease in chronic hepatitis C (HCV)
      patients. Levels of AFB1-albumin/albumin were significantly related to ultrasono-graphic
      hepatic parenchyma scores in anti-HCV-positive subjects .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No Masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Aflatoxin Level in Liver Cancer Patients</measure>
    <time_frame>6 months</time_frame>
    <description>Serum aflatoxin level in liver cancer patients in comparison to liver cirrhosis and controls.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Hepatocellular carcinoma (HCC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 cirrhotic patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Estimation of serum aflatoxin level in 20 patients with liver cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aflatoxin</intervention_name>
    <description>Evaluation of Aflatoxin level</description>
    <arm_group_label>Hepatocellular carcinoma (HCC)</arm_group_label>
    <arm_group_label>20 cirrhotic patients</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cirrhotic patient with and without HCC

        Exclusion Criteria:

          -  Malignancy other than HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Sharaf-eldin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raafat Salah, Professor</last_name>
    <role>Study Director</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>hanan Soliman, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief abd-elsalm, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walaa Elkhalawany, lecturer</last_name>
    <role>Study Chair</role>
    <affiliation>hepatology dept-Tanta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta university - faculty of medicine</name>
      <address>
        <city>Cairo</city>
        <state>Elgharbia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>October 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 17, 2017</results_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>sponsor investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hepatocellular Carcinoma (HCC)</title>
          <description>Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC)
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="P2">
          <title>Cirrhotic Patients</title>
          <description>Estimation of serum aflatoxin level in 80 patients with liver cirrhosis
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hepatocellular Carcinoma (HCC)</title>
          <description>Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC)
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="B2">
          <title>Cirrhotic Patients</title>
          <description>Estimation of serum aflatoxin level in 80 patients with liver cirrhosis
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age, categorical numerical</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.58" spread="9.58"/>
                    <measurement group_id="B2" value="50.00" spread="8.72"/>
                    <measurement group_id="B3" value="27.80" spread="5.06"/>
                    <measurement group_id="B4" value="45" spread="23.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Aflatoxin Level in Liver Cancer Patients</title>
        <description>Serum aflatoxin level in liver cancer patients in comparison to liver cirrhosis and controls.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hepatocellular Carcinoma (HCC)</title>
            <description>Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC)
Aflatoxin: Evaluation of Aflatoxin level</description>
          </group>
          <group group_id="O2">
            <title>80 Cirrhotic Patients</title>
            <description>Estimation of serum aflatoxin level in 80 patients with liver cirrhosis
Aflatoxin: Evaluation of Aflatoxin level</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
Aflatoxin: Evaluation of Aflatoxin level</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Aflatoxin Level in Liver Cancer Patients</title>
          <description>Serum aflatoxin level in liver cancer patients in comparison to liver cirrhosis and controls.</description>
          <units>ng\ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" spread="2.06"/>
                    <measurement group_id="O2" value="6.10" spread="1.71"/>
                    <measurement group_id="O3" value="4.13" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>0 means no side effects</desc>
      <group_list>
        <group group_id="E1">
          <title>Hepatocellular Carcinoma (HCC)</title>
          <description>Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC)
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="E2">
          <title>Cirrhotic Patients</title>
          <description>Estimation of serum aflatoxin level in 80 patients with liver cirrhosis
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
Aflatoxin: Evaluation of Aflatoxin level</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sherief Abd-Elsalam</name_or_title>
      <organization>Tanta university</organization>
      <phone>00201095159522</phone>
      <email>sherif_tropical@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

